9-Sep-2026
TipRanks (Tue, 8-Sep 9:10 AM ET)
The Week That Was, The Week Ahead: Macro and Markets, September 6
TipRanks (Sun, 6-Sep 4:37 AM ET)
BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
PRNewswire (Thu, 27-Aug 6:50 AM ET)
BD to Present at Wells Fargo 21st Annual Healthcare Conference
PRNewswire (Wed, 26-Aug 4:15 PM ET)
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
PRNewswire (Mon, 17-Aug 4:30 PM ET)
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
PRNewswire (Wed, 12-Aug 6:50 AM ET)
BD Reports Third Quarter Fiscal 2026 Financial Results
PRNewswire (Thu, 6-Aug 6:30 AM ET)
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
PRNewswire (Wed, 29-Jul 6:56 AM ET)
PRNewswire (Tue, 28-Jul 4:15 PM ET)
Mike Garrison to Retire from BD
PRNewswire (Wed, 22-Jul 6:55 AM ET)
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Becton Dickinson And Company trades on the NYSE stock market under the symbol BDX.
As of September 9, 2026, BDX stock price climbed to $179.80 with 1,415,918 million shares trading.
BDX has a beta of 0.18, meaning it tends to be less sensitive to market movements. BDX has a correlation of 0.01 to the broad based SPY ETF.
BDX has a market cap of $51.15 billion. This is considered a Large Cap stock.
Last quarter Becton Dickinson And Company reported $5 billion in Revenue and $3.23 earnings per share. This beat revenue expectation by $96 million and exceeded earnings estimates by $.10.
In the last 3 years, BDX traded as high as $269.52 and as low as $140.11.
The top ETF exchange traded funds that BDX belongs to (by Net Assets): VTI, VOO, VO, SPY, VTV.
BDX has outperformed the market in the last year with a return of +19.9%, while the SPY ETF gained +18.4%. In the last 3 month period, BDX beat the market returning +18.9%, while SPY returned +3.7%. However, in the most recent 2 weeks BDX has underperformed the stock market by returning -4.9%, while SPY returned -0.5%.
BDX support price is $175.02 and resistance is $181.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDX shares will trade within this expected range on the day.
